Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.

Webcast ImageWebcast
Cynosure Inc. at Canaccord Genuity Growth Conference (Replay)
08/13/14 at 3:30 p.m. ET
Cynosure Inc. at Canaccord Genuity Growth Conference
Wednesday, August 13, 2014 3:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
CYNO (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$22.53
Change (%) Stock is Up 0.22 (0.99%)
Volume125,900
Data as of 08/29/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

News Releases

August 06, 2014
Cynosure to Present at Canaccord Genuity 34th Annual Growth Conference
July 30, 2014
Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President
July 29, 2014
Cynosure Reports Second-Quarter 2014 Financial Results

Upcoming Events

There are currently no events scheduled.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.